Our Team

We are experienced clinicians and researchers—specialists in infectious disease, genomics and next-generation sequencing technologies—who are passionate about leveraging the power of technology to advance human health and quality of life.

Crystal R Icenhour, PhD
CEO and Co-Founder
Crystal R Icenhour, PhD
CEO and Co-Founder

Dr. Crystal R. Icenhour, Ph.D. is one of the rising stars of American biotechnology. As founding CEO of Aperiomics, she brings more than 25 years in medical research and leads the company’s mission to harness the power of next-generation DNA sequencing to identify every known pathogen – bacteria, virus, fungi or parasite – within a single test.

Throughout Dr. Icenhour’s career, she has been a leader in both business and science, bridging the translational gap between these two worlds through technology. A seasoned entrepreneur, she previously served as President and Chief Science Officer for Phthisis Diagnostics in Charlottesville, Virginia – a research and development company developing easy-to-use molecular diagnostics for intestinal parasites. Dr. Icenhour holds two patents, has authored and co-authored numerous research articles and theses, and has been a prolific speaker and presenter at scientific conferences. She has served on review panels for the National Science Foundation, the Environmental Protection Agency, and National Institutes of Health Small Business Innovation Research Program.

Dr. Icenhour serves as Chairman of Virginia BIO and was chosen to participate in the Springboard Enterprises 2016 class of women-led companies. She received her Ph.D. in Pathobiology and Molecular Medicine from the University of Cincinnati Medical School of Graduate Studies in 2002. Following the completion of her graduate degree, Dr. Icenhour conducted postdoctoral research at the Mayo Clinic College of Medicine and the Department of Infectious Diseases at Duke University Medical Center, where she currently serves as an adjunct assistant professor.

Yuan (Alvin) Chen, PhD
CTO and Co-Founder
Yuan (Alvin) Chen, PhD
CTO and Co-Founder

With more than 10 years of experience in next-generation DNA sequencing, Dr. Alvin Chen, Ph.D. is an expert in genomics, genetics and bioinformatics. He joined Aperiomics in 2015, serving as the Principal Investigator for the company’s National Science Foundation Small Business Innovation (Phase II) grant. Dr. Chen successfully developed Aperiomics’ primary platform, Xplore-PATHO℠, which uses DNA sequencing technology to identify all known microbes in a single test. In his role as Chief Technology Officer, he leads the development of the company’s information management systems.

Prior to joining Aperiomics, Dr. Chen managed several scientific research projects, resulting in more than 15 articles in high-impact, peer-reviewed journals such as PLoS Genetics, Genome Research, MBio, Nature Communications and Molecular Ecology. He is a passionate programmer with more than 25 years of experience, leading and participating in multiple software development projects. He is proficient in numerous programming languages with a robust background in developing hardware and system architecture.

Dr. Chen received his Ph.D. from the Graduate University of Chinese Academy of Sciences in 2012 and served as Postdoctoral Fellow at Duke University Medical Center’s Division of Infectious Diseases from 2012-2015.

C. Alexander Valencia, PhD
Chief Clinical Officer
C. Alexander Valencia, PhD
Chief Clinical Officer

Dr. C. Alexander Valencia, Ph.D. is a skilled molecular geneticist and an expert in translating next-generation sequencing technology into clinical practice through the development and implementation of clinical assays, interpretation of genomic data and by associating novel genes to human diseases. As Aperiomics’ Chief Clinical Officer, he oversees clinical test development, validations, regulatory affairs and operations on behalf of the company.

With over a decade of administration experience in major laboratories across the United States, Dr. Valencia has managed teams of technologists, project managers, genetic counselors, marketing specialists, and bioinformaticians. Prior to joining Aperiomics, he served as the molecular laboratory director at Cincinnati Children’s Hospital Medical Center and PerkinElmer Genomics. Setting the standard for genetics in medical practice, Dr. Valencia has made significant contributions in the field of clinical genomics, publishing more than 50 peer-reviewed articles and speaking at numerous conferences.

Dr. Valencia received his Ph.D. from Carleton University and the University of Ottawa and completed his post-doctoral studies in biochemistry/molecular biology and clinical molecular genetics at the University of North Carolina Chapel Hill and Emory University, respectively.

Elizabeth P Pyle
Chief Operating Officer
Elizabeth P Pyle
Chief Operating Officer

Elizabeth P. Pyle is a seasoned executive with an extensive background in business development, strategic planning, marketing, and operations management. In her role as Aperiomics’ Chief Operating Officer, Ms. Pyle oversees corporate operations and quality assurance of Aperiomics’ DNA-testing services.

Prior to joining Aperiomics, Ms. Pyle directed the University of Virginia’s National Science Foundation Innovation-Corps Program, designing undergraduate and graduate curricula for the School of Engineering & Applied Sciences’ Technology Entrepreneurship Program. She also founded Pyle & Associates, LLC – an Interim Executive Management firm providing customized consulting for clients operating across several diversified industries.

Ms. Pyle holds a M.B.A. degree from Averett University, a M.Ed. from the University of Houston, and a B.A. in Geology from Cedar Crest College. She has served on various boards including the Board of Directors for the Charlottesville Venture Group, where she chaired the Business Plan Review and Annual Business Forum Committees.

Alexander Larsen
Clinical Bioinformatician II
Alexander Larsen
Clinical Bioinformatician II

Alexander Larsen is a bioinformatics specialist supporting Aperiomics’ evaluation of DNA-related data that the company receives every day from doctors and their patients worldwide. In his role as a clinical bioinformatician, Mr. Larsen conducts statistical analyses of metagenomic sequencing data as it relates to symptoms of disease. He also helps with bioinformatic programming and tool design, as well as in-house scientific research and business development.

Before joining Aperiomics, Mr. Larsen was an undergraduate researcher at the University of Wisconsin-Madison, where he assisted the research lab in characterizing circadian rhythm genes and their temporal effects on long-term memory formation, worked with processing samples, and supported data analysis, western blotting, and research publication writing.

Mr. Larsen earned a B.S. degree in Neurobiology from the University of Wisconsin-Madison, where he graduated from the honors Biocore biology program. Larsen has also taken graduate studies in bioinformatics.

David Baugher
Data Scientist
David Baugher
Data Scientist

David Baugher is a data scientist on the tech team at Aperiomics, where he is focused on designing, developing, and maintaining machine learning pipelines that support the clinical team’s patient report generation. Mr. Baugher oversees Aperiomics’ use of natural language processing and other machine learning methods that are crucial in informing the clinical team around the relevance of microbes found in Aperiomics’ DNA testing services, ensuring reports are as informative to clinicians as possible. His role also includes performing ad hoc data analysis and application development as necessary for the support of both the sales and clinical teams.

Prior to joining Aperiomics, Mr. Baugher worked in a variety of industries including petroleum and telecommunications, specializing in data analytics, data modeling, and software development.

Mr. Baugher has B.S. degrees in both Applied Mathematics and Geophysics from Texas A&M University. He has supported grad research for the Psychology Department at the University of Texas Austin and is working on a M.S. of Computer Science at the Georgia Institute of Technology.

Andy Berger
Operations Specialist
Andy Berger
Operations Specialist
Kerrie Miller
Office Manager
Kerrie Miller
Office Manager

Board of Directors

Dr. Keith Crandall, PhD
Co-Founder
Dr. Keith Crandall, PhD
Co-Founder
Crystal R Icenhour, PhD
CEO and Co-Founder
Crystal R Icenhour, PhD
CEO and Co-Founder

Dr. Crystal R. Icenhour, Ph.D. is one of the rising stars of American biotechnology. As founding CEO of Aperiomics, she brings more than 25 years in medical research and leads the company’s mission to harness the power of next-generation DNA sequencing to identify every known pathogen – bacteria, virus, fungi or parasite – within a single test.

Throughout Dr. Icenhour’s career, she has been a leader in both business and science, bridging the translational gap between these two worlds through technology. A seasoned entrepreneur, she previously served as President and Chief Science Officer for Phthisis Diagnostics in Charlottesville, Virginia – a research and development company developing easy-to-use molecular diagnostics for intestinal parasites. Dr. Icenhour holds two patents, has authored and co-authored numerous research articles and theses, and has been a prolific speaker and presenter at scientific conferences. She has served on review panels for the National Science Foundation, the Environmental Protection Agency, and National Institutes of Health Small Business Innovation Research Program.

Dr. Icenhour serves as Chairman of Virginia BIO and was chosen to participate in the Springboard Enterprises 2016 class of women-led companies. She received her Ph.D. in Pathobiology and Molecular Medicine from the University of Cincinnati Medical School of Graduate Studies in 2002. Following the completion of her graduate degree, Dr. Icenhour conducted postdoctoral research at the Mayo Clinic College of Medicine and the Department of Infectious Diseases at Duke University Medical Center, where she currently serves as an adjunct assistant professor.

George Lula
Director
George Lula
Director
Stacy Baines Manvitz
Director
Stacy Baines Manvitz
Director

Science Advisory Board

Dr. Evan Johnson, PhD, Chairman
Chairman, Co-Founder
Dr. Evan Johnson, PhD, Chairman
Chairman, Co-Founder
Dr. Keith Crandall, PhD
Co-Founder
Dr. Keith Crandall, PhD
Co-Founder
Yuan (Alvin) Chen, PhD
CTO and Co-Founder
Yuan (Alvin) Chen, PhD
CTO and Co-Founder

With more than 10 years of experience in next-generation DNA sequencing, Dr. Alvin Chen, Ph.D. is an expert in genomics, genetics and bioinformatics. He joined Aperiomics in 2015, serving as the Principal Investigator for the company’s National Science Foundation Small Business Innovation (Phase II) grant. Dr. Chen successfully developed Aperiomics’ primary platform, Xplore-PATHO℠, which uses DNA sequencing technology to identify all known microbes in a single test. In his role as Chief Technology Officer, he leads the development of the company’s information management systems.

Prior to joining Aperiomics, Dr. Chen managed several scientific research projects, resulting in more than 15 articles in high-impact, peer-reviewed journals such as PLoS Genetics, Genome Research, MBio, Nature Communications and Molecular Ecology. He is a passionate programmer with more than 25 years of experience, leading and participating in multiple software development projects. He is proficient in numerous programming languages with a robust background in developing hardware and system architecture.

Dr. Chen received his Ph.D. from the Graduate University of Chinese Academy of Sciences in 2012 and served as Postdoctoral Fellow at Duke University Medical Center’s Division of Infectious Diseases from 2012-2015.

Founders

Dr. Keith Crandall, PhD
Co-Founder
Dr. Keith Crandall, PhD
Co-Founder
Crystal R Icenhour, PhD
CEO and Co-Founder
Crystal R Icenhour, PhD
CEO and Co-Founder

Dr. Crystal R. Icenhour, Ph.D. is one of the rising stars of American biotechnology. As founding CEO of Aperiomics, she brings more than 25 years in medical research and leads the company’s mission to harness the power of next-generation DNA sequencing to identify every known pathogen – bacteria, virus, fungi or parasite – within a single test.

Throughout Dr. Icenhour’s career, she has been a leader in both business and science, bridging the translational gap between these two worlds through technology. A seasoned entrepreneur, she previously served as President and Chief Science Officer for Phthisis Diagnostics in Charlottesville, Virginia – a research and development company developing easy-to-use molecular diagnostics for intestinal parasites. Dr. Icenhour holds two patents, has authored and co-authored numerous research articles and theses, and has been a prolific speaker and presenter at scientific conferences. She has served on review panels for the National Science Foundation, the Environmental Protection Agency, and National Institutes of Health Small Business Innovation Research Program.

Dr. Icenhour serves as Chairman of Virginia BIO and was chosen to participate in the Springboard Enterprises 2016 class of women-led companies. She received her Ph.D. in Pathobiology and Molecular Medicine from the University of Cincinnati Medical School of Graduate Studies in 2002. Following the completion of her graduate degree, Dr. Icenhour conducted postdoctoral research at the Mayo Clinic College of Medicine and the Department of Infectious Diseases at Duke University Medical Center, where she currently serves as an adjunct assistant professor.

Yuan (Alvin) Chen, PhD
CTO and Co-Founder
Yuan (Alvin) Chen, PhD
CTO and Co-Founder

With more than 10 years of experience in next-generation DNA sequencing, Dr. Alvin Chen, Ph.D. is an expert in genomics, genetics and bioinformatics. He joined Aperiomics in 2015, serving as the Principal Investigator for the company’s National Science Foundation Small Business Innovation (Phase II) grant. Dr. Chen successfully developed Aperiomics’ primary platform, Xplore-PATHO℠, which uses DNA sequencing technology to identify all known microbes in a single test. In his role as Chief Technology Officer, he leads the development of the company’s information management systems.

Prior to joining Aperiomics, Dr. Chen managed several scientific research projects, resulting in more than 15 articles in high-impact, peer-reviewed journals such as PLoS Genetics, Genome Research, MBio, Nature Communications and Molecular Ecology. He is a passionate programmer with more than 25 years of experience, leading and participating in multiple software development projects. He is proficient in numerous programming languages with a robust background in developing hardware and system architecture.

Dr. Chen received his Ph.D. from the Graduate University of Chinese Academy of Sciences in 2012 and served as Postdoctoral Fellow at Duke University Medical Center’s Division of Infectious Diseases from 2012-2015.

Dr. Evan Johnson, PhD, Chairman
Chairman, Co-Founder
Dr. Evan Johnson, PhD, Chairman
Chairman, Co-Founder
Eduardo Castro-Nallar
Co-Founder
Eduardo Castro-Nallar
Co-Founder